Longevity Investors Conference

Startseite
Schweiz
Zug
Longevity Investors Conference

Creating premier platforms for the most prominent investors in the longevity field.│Join the Longevity Investors Conference, Sept 22-25 in Gstaad!

08/09/2026

Five conference passes left. Here is what they open.

Nir Barzilai, Jordan Shlain, Adeel Khan and David Barzilai take apart what the same patient costs across academia, a private clinic and concierge medicine. Steve Horvath, Collin Ewald and Evelyne Bischof on spotting real aging science. Jonathan Anomaly, Michael Levin, Yossi Yamin and Alice Gilman on longevity's boldest bets. An hour with Dave Asprey on where longevity, AI and human performance go next. Sophie Chabloz, David Cox and Jan Ge**er on how much life you are sacrificing to live longer.

Then the roundtables, led by the speakers and kept deliberately small. Asprey and Natalie Lefevre on signal versus noise. Khan and Marchione on peptides. Zmudze on the next unicorns. Reichmuth on longevity built into real estate.

Mountain lunch at Wasserngrat. Cold exposure in the Saane. The Gala.

Some of these conversations do not happen anywhere else.

Swipe for the full agenda. Le Grand Bellevue is fully booked, five conference passes left at late bird pricing.
longevityinvestors.ch/lic-2026

04/09/2026

Ten days until the longevity community gathers again at Le Grand Bellevue.

On stage: Dr. Aubrey de Grey, Dr. Steve Horvath, Dr. Nir Barzilai, Michael Ringel of Life Biosciences, Philipp Gut of Nestlé Research, Dr. Collin Ewald of Novartis Biomedical Research, Nachson Mimran and more than thirty others.

Accommodation packages are fully booked. A small number of conference-only passes remain, covering the full programme, the roundtables and the networking.

At the roundtables: Dave Asprey and Natalie Lefevre on signal versus noise. Dr. Adeel Khan and Max Marchione on peptides. Garri Zmudze on the next longevity unicorns. Dr. Tobias Reichmuth on longevity real estate. Prof. Evelyne Bischof with The Longevity Doctor's Office, an open Q&A for investors and innovators.

Training and recovery with THE UNIT across all three days. A mountain-top lunch at Wasserngrat. A sunset reception on The MANSARD rooftop. The Gala Celebration, a tombola, and a world premiere we have kept quiet.

Late registration pricing applies from 7 September.
Details and application: longevityinvestors.ch/lic-2026

31/08/2026

Drugs that target aging, blood purification, AI coaching, next-generation diagnostics. The 2026 Startup Innovation Catalyst spans the whole field: eight companies, carefully selected from many, joining us at LIC 2026.

GERO, a physics-first AI biotech designing drugs that target aging itself, with pharma collaborations including Chugai and Pfizer.
AGENTLY, an outpatient blood-purification protocol that clears the endotoxins and inflammatory drivers behind age-related disease, developed by Efferon, whose devices have run over 25,000 intensive-care procedures.
GEVITY, a premium membership club bringing evidence-based preventive health and diagnostics under one roof.
NewAgy, an AI longevity coach that turns everything known about you into a single daily decision: what to do today.
KEYONIQ, proprietary biological-age diagnostics and a clinical decision engine that turns the data into real care pathways.
Longevity Life Sciences, a cellular-health platform built around CellVive NMN, the first NMN supplied under Australia's therapeutic-ingredient pathway.
ieumBio, using short-lived vertebrate models to test healthspan interventions in a fraction of the usual time.
LIVIUS, translating four decades of microRNA and epigenetics research into real-world use across cosmetics, clinical and cell processing.

LIC 2026, 14-17 September. Application-only.
Apply to join → longevityinvestors.ch/lic-2026

28/08/2026

Every great conversation needs someone to steer it, and three days of them need real range.

Leading LIC 2026 as Master of Ceremonies is Sabinije von Gaffke, founder of Impactfulness Ventures and an award-winning broadcast journalist and facilitator who keeps the whole conference moving, on stage and between the sessions. Alongside her, Hilary Brueck, Health Correspondent at Business Insider and one of the sharpest longevity reporters working today, steers the panels.

Carrying those conversations to the world are our media partners, Longevity.Technology, the field's most-read publication, and The Horizons Life, because what is said at LIC should not stay at LIC.

And the world is already listening. From Business Insider to finews to Unfiltered, the press is watching LIC 2026 closely, including the new Longevity.Technology UNLOCKED episode, "The $51M Bet to Make the Doctor Obsolete."

Don't just watch. Join.

Longevity Investors Conference, 14-17 September, Gstaad. Application-only.

Links in Bio.

26/08/2026

Seven years ago, building a conference around longevity looked early. Dr. Tobias Reichmuth and Marc P. Bernegger, Founding Partners of Maximon and Longevity Investors, made it anyway.

The bet was simple and, at the time, unproven: that longevity science and the capital to move it belonged in the same room, and almost nowhere put them there. LIC became that room, run by CEO Lucia Kupcova and hosted from the very first year at Daniel Koetser's Le Grand Bellevue in Gstaad.

If you build, fund or study longevity, this is your gathering. This September, the people funding the future gather to shape it, for the seventh time.
Join us.

LIC 2026, 14-17 September, Gstaad.
→ longevityinvestors.ch/lic-2026

24/08/2026

The missed dinner. The sleep score turned into anxiety. The supplement stack that became a second job.

Every longevity protocol has a cost. "The Longevity Tax" asks the question the industry rarely says out loud: at what point does chasing more years start eating into the years you are actually living? Which practices are genuinely worth it, and which are just noise?

With Sophie Chabloz , David Cox and Jan Ge**er.

LIC 2026, 14-17 September, Gstaad. Application-only.
longevityinvestors.ch/lic-2026

21/08/2026

18 months to design a longevity drug. Years to prove it works. Billions being invested in the gap.

AI made finding a drug fast. It did nothing to the clinical proof that decides whether it pays. Our new piece maps the 2026 AI longevity field: Insilico, Retro Biosciences, NewLimit, BioAge and Gero.

Insilico's AI drug reached Phase 2 and IPO'd for $293M. NewLimit hit a $3.1B valuation while still preclinical. $3.74B flowed into longevity in one quarter, and zero AI-discovered drugs have been proven to slow aging.

What AI has de-risked is the chemistry, not the biology. Full read: New on LINews.

18 months to design a longevity drug. Years to know whether it works. Billions are being invested in the gap.

AI has made finding a drug fast and cheap, and done nothing to the clinical proof that decides whether it pays. The piece maps the field in 2026, from Insilico, Retro Biosciences, NewLimit, BioAge and Gero: Insilico's drug at Phase 2, NewLimit at a $3.1B valuation while still preclinical, $3.74B into longevity in a single quarter, and not one AI-discovered drug yet shown to slow aging.

What AI has de-risked is the chemistry, not the biology.

Read it here → https://www.longevityinvestorsnews.ch/post/ai-longevity-drug-race-2026

19/08/2026

We can measure more about our health than ever. The hard part is what happens next.

"Lost in Translation" asks where consumer longevity loses most of its value, in the gap between the data we gather and the action we take on it, and where the next businesses will be built.

With Nachson Mimran (The Alpina Gstaad), Max Marchione (Superpower) and Dr. Sherry Zhang (GenoPalate).

LIC 2026, 14-17 September, Gstaad. Application-only.
Experience it for yourself, apply to join: longevityinvestors.ch/lic-2026

17/08/2026

Longevity used to be a niche. Not anymore. People are spending real money on supplements, nutrition and health services that promise to help them age better.

So the investor question has changed. Not whether consumer longevity is a market, but which channels are building durable businesses, and which are riding a wave that breaks before 2030.

"Longevity Goes Mainstream" brings that question to Gstaad with Philipp Gut, Rob Fried, Marc P. Bernegger and Manjit Sareen.

LIC 2026, 14-17 September. Application-only. longevityinvestors.ch/lic-2026

14/08/2026

One month out, and this is who you'll meet.

The 2026 line-up is here, and it's worth pausing on who's in it. The scientists working at the root of aging, the clinicians treating it, the founders turning that science into companies, and the investors deciding what gets built next. People who usually only cross paths across a paper or a term sheet, together in the same rooms for three days.

That mix is the whole point. The science means little without the capital to move it, and the capital is only as good as its read on the science. This is where the two sit down together.

More names still to come. A few seats remain, application-only and reviewed individually.

LIC 2026, 14-17 September, Gstaad.
Apply to join: longevityinvestors.ch/lic-2026

Adresse

Bahnhofplatz
Zug
6300

Webseite

https://www.longevityinvestors.ch/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Longevity Investors Conference erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.